Blood coagulation system state in breast cancer patients that recovered from coronaviral infection after undergoing antitumor medical treatment
Open Access
- 17 August 2022
- journal article
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 9 (3), 25-38
- https://doi.org/10.17709/2410-1893-2022-9-3-2
Abstract
Purpose of the study. An analysis of parameters of the blood coagulation system in breast cancer patients after coronavirus disease.Materials and methods. 50 breast cancer patients were divided into groups: the main group included 30 patients after coronavirus disease, the control group 1–20 patients without confirmed COVID‑19, and control group 2–20 non-cancer women after corona‑ virus disease. All cancer patients received appropriate chemotherapy. The following parameters were studied: activated partial thromboplastin time (APTT), prothrombin time (PT), international normalized ratio (INR), prothrombin index (PTI), fibrinogen, soluble fibrin monomer complexes (SFMCs), thrombin time (TT), antithrombin III, D-dimer and plasminogen, fibrin degradation products. Blood tests were performed 4–6 weeks after the infection and two negative PCR test results for COVID‑19.Results. Patients of the main group demonstrated differences in INR values after treatment in the subgroups with asymptomatic disease (Me = 1.24) and with mild symptoms (Me = 0.97) U = 10; Z = 2.766; р = 0.0057, in subgroups with asymptomatic disease (Me = 1.24) and with moderate to severe symptoms (Me = 0.98) U = 26.5; Z = 2.199; р = 0.027, and in TT values in subgroups with asymptomatic disease (Me = 14.5) and with moderate to severe symptoms (Me = 16.5) U = 18.5; Z = –2.725; р = 0.0064. The comparison of the parameters in patients after COVID‑19 before (Me = 0.83) and after treatment (Me = 0.4) showed differences in the D-dimer values in patients with moderate to severe disease U = 6.5; Z = –2.2861; р = 0.022 towards their decrease after the therapy. Differences were found in APTT values between the main group (Me = 30.65) and control group 1 (Me = 27.85) U = 119; Z = 3.574; р = 0.00035, in antithrombin values between the main group (Me = 94) and control group 1 (Me = 106) U = 112; Z = 3.713; р = 0.00021, and in SFMCs values between the main group (Me = 17) and control group 1 (Me = 8) U = 180.5; Z = 2.356; р = 0.018.Conclusions. Determination of plasminogen levels can become an independent factor in detecting thrombotic risk in cancer patients who recovered from COVID‑19. Previous infection with COVID‑19 should be considered an additional risk factor for venous thromboembolic complications for cancer patients.This publication has 16 references indexed in Scilit:
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- COVID-19 and the liver: little cause for concernThe Lancet Gastroenterology & Hepatology, 2020
- Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 PandemicJournal of the American College of Cardiology, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- Circulating tumour cells and hypercoagulability: a lethal relationship in metastatic breast cancerClinical and Translational Oncology, 2019
- Targeting clotting proteins in cancer therapy – progress and challengesThrombosis Research, 2016
- Relationship between Circulating Tumor Cells, Blood Coagulation, and Urokinase-Plasminogen-Activator System in Early Breast Cancer PatientsThe Breast Journal, 2015
- Priorities for the primary prevention of breast cancerCA: A Cancer Journal for Clinicians, 2014
- Incidence of venous thromboembolism in patients with cancer – A cohort study using linked United Kingdom databasesEuropean Journal of Cancer, 2012
- Inflammation and coagulationCritical Care Medicine, 2010